Oncternal Therapeutics Inc Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/26/2024)
| Balance Sheet | Total Assets | 36,729,000.00 | ROE | – |
| Balance Sheet | Total Equity | 30,052,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -1.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -32,164,000.00 | – | – |
| Cashflow | Operating Cash Flow | -32,164,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -14.89 | Div. Yield | – |
| Income | Net Income | -39,479,000.00 | P/E | – |
| Income | Shares Outstanding | 2,651,020.00 | P/B | – |
| Income | Total Revenue | 785,000.00 | P/S | – |
Ratios calculated on: –
Company Description
GTx, Inc. is a biopharmaceutical company. The Company is developing selective androgen receptor modulators (SARMs) , a drugs with the potential to prevents and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). The Company is conducting the POWER 1 and POWER 2 (Prevention and treatment Of muscles Wasting in patients with cancER) pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer. In October 2012, it sold rights and related assets in the metastatic breast cancer product, Fareston, to ProStrakan Group plc.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.gtxinc.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more